OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects With Neovascular Age-Related Macular Degeneration (AMD)

Trial Profile

OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects With Neovascular Age-Related Macular Degeneration (AMD)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Squalamine (Primary) ; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms MAKO
  • Sponsors Ohr Pharmaceutical
  • Most Recent Events

    • 12 Dec 2017 Acording to Ohr Pharmaceutical media release, topline data from this study is expected in early 2018.
    • 11 May 2017 According to an Ohr Pharmaceutical media release, the trial protocol has been amended to enable top-line data (efficacy analyses) by the end of calendar 2017 or early 2018. Patients enrolled in the study continue to receive their assigned study treatment of monthly Lucentis and either topical Squalamine or placebo twice daily, and undergo scheduled visits and assessments through nine months.
    • 25 Apr 2017 Planned End Date changed from 1 Apr 2019 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top